ATAI Life Sciences NV (ATAI)
1.645
+0.02
(+0.92%)
USD |
NASDAQ |
May 16, 16:00
1.645
0.00 (0.00%)
After-Hours: 16:36
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 326.21M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -20.49% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 2.805 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.202 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. |
URL | https://www.atai.life |
Investor Relations URL | https://ir.atai.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Next Earnings Release | Aug. 13, 2025 (est.) |
Last Earnings Release | May. 14, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. |
URL | https://www.atai.life |
Investor Relations URL | https://ir.atai.com/ |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Pharmaceuticals |
Next Earnings Release | Aug. 13, 2025 (est.) |
Last Earnings Release | May. 14, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |